Related Experiment Video
Updated: Apr 23, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.2K
Classics in chemical neuroscience: levodopa
A Connor Whitfield1, Ben T Moore, R Nathan Daniels
1Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences , Nashville, Tennessee 37204, United States.
ACS Chemical Neuroscience
|October 2, 2014
Summary
Levodopa remains the gold standard for Parkinson's disease (PD) treatment, significantly improving symptoms by enhancing dopamine levels. Its combination with carbidopa reduced side effects, making it a cornerstone therapy for over 50 years.
Area of Science:
- Neuroscience
- Pharmacology
- Medical History
Background:
- Parkinson's disease (PD) affects approximately 1 million individuals in the United States.
- Effective treatments for Parkinson's disease were lacking before the discovery of levodopa.
- PD was first described in 1817, highlighting a long-standing need for therapeutic interventions.
Observation:
- In 1961, levodopa was pioneered to increase dopamine levels in the striatum, offering significant symptom improvement for PD patients.
- The addition of carbidopa in 1974 substantially decreased gastrointestinal adverse drug reactions (ADRs).
- Levodopa therapy, established over five decades ago, continues to be the primary treatment for Parkinson's disease.
Findings:
- Levodopa's synthesis, metabolism, and pharmacology are crucial for its therapeutic efficacy.
- Understanding levodopa's adverse drug reactions (ADRs) is essential for patient management.
- The historical and ongoing importance of levodopa therapy in neuroscience is well-documented.
Implications:
- Levodopa therapy represents a major advancement in managing Parkinson's disease symptoms.
- The development of levodopa and its combination with carbidopa revolutionized PD treatment.
- This review details the multifaceted aspects of levodopa, underscoring its enduring significance in neurology and pharmacology.
More Related Videos
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:24Parkinson Disease ll: Pathophysiology
13
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
13
01:15Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
01:24Parkinson Disease l: Introduction
6
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
6
01:26Neurochemical Transmission: Sites of Drug Action
3.4K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K